Human Chondrocytes from Human Adipose Tissue-Derived Mesenchymal Stem Cells Seeded on a Dermal-Derived Collagen Matrix Sheet: Our Preliminary Results for a Ready to Go Biotechnological Cartilage Graft in Clinical Practice.
Journal
Stem cells international
ISSN: 1687-966X
Titre abrégé: Stem Cells Int
Pays: United States
ID NLM: 101535822
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
11
2020
revised:
16
12
2020
accepted:
06
02
2021
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
epublish
Résumé
The articular cartilage is unique in that it contains only a single type of cell and shows poor ability for spontaneous healing. Cartilage tissue engineering which uses mesenchymal stem cells (MSCs) and adipose tissue-derived mesenchymal stem cells (AT-MSCs) is considered an attractive treatment for cartilage lesions and osteoarthritis. The establishment of cartilage regenerative medicine is an important clinical issue, but the search for cell sources able to restore cartilage integrity proves to be challenging. The aim of this study was to create cartilage grafts from the combination of AT-MSCs and collagen substrates. Mesenchymal stem cells were obtained from human donors' adipose tissue, and collagen scaffold, obtained from human skin and cleaned from blood vessels, adipose tissues, and debris, which only preserve dermis and epidermis, were seeded and cultured on collagen substrates and differentiated to chondrocytes. The obtained chondrocyte extracellular matrix of cartilage was then evaluated for the expression of chondrocyte-/cartilage-specific markers, the Cartilage Oligomeric Matrix Protein (COMP), collagen X, alpha-1 polypeptide (COL10A1), and the Collagen II, Human Tagged ORF Clone (COL2A1) by using the reverse transcription polymerase chain reaction (RT-PCR). Our findings have shown that the dermal collagen may exert important effects on the quality of in vitro expanded chondrocytes, leading in this way that the influence of collagen skin matrix helps to produce highly active and functional chondrocytes for long-term cartilage tissue regeneration. This research opens up the possibility of generating cartilage grafts with the precise purpose of improving the existing limitation in current clinical procedures.
Sections du résumé
BACKGROUND
BACKGROUND
The articular cartilage is unique in that it contains only a single type of cell and shows poor ability for spontaneous healing. Cartilage tissue engineering which uses mesenchymal stem cells (MSCs) and adipose tissue-derived mesenchymal stem cells (AT-MSCs) is considered an attractive treatment for cartilage lesions and osteoarthritis. The establishment of cartilage regenerative medicine is an important clinical issue, but the search for cell sources able to restore cartilage integrity proves to be challenging. The aim of this study was to create cartilage grafts from the combination of AT-MSCs and collagen substrates.
METHODS
METHODS
Mesenchymal stem cells were obtained from human donors' adipose tissue, and collagen scaffold, obtained from human skin and cleaned from blood vessels, adipose tissues, and debris, which only preserve dermis and epidermis, were seeded and cultured on collagen substrates and differentiated to chondrocytes. The obtained chondrocyte extracellular matrix of cartilage was then evaluated for the expression of chondrocyte-/cartilage-specific markers, the Cartilage Oligomeric Matrix Protein (COMP), collagen X, alpha-1 polypeptide (COL10A1), and the Collagen II, Human Tagged ORF Clone (COL2A1) by using the reverse transcription polymerase chain reaction (RT-PCR).
RESULTS
RESULTS
Our findings have shown that the dermal collagen may exert important effects on the quality of in vitro expanded chondrocytes, leading in this way that the influence of collagen skin matrix helps to produce highly active and functional chondrocytes for long-term cartilage tissue regeneration.
CONCLUSION
CONCLUSIONS
This research opens up the possibility of generating cartilage grafts with the precise purpose of improving the existing limitation in current clinical procedures.
Identifiants
pubmed: 33679990
doi: 10.1155/2021/6664697
pmc: PMC7929680
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6664697Informations de copyright
Copyright © 2021 Quan Tran Dang et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Curr Stem Cell Res Ther. 2020;15(1):54-60
pubmed: 31660820
3 Biotech. 2020 Apr;10(4):161
pubmed: 32206495
Arthritis Rheum. 2010 May;62(5):1421-30
pubmed: 20131279
J Bone Joint Surg Am. 2003 Nov;85(11):2111-20
pubmed: 14630839
HSS J. 2016 Jul;12(2):150-7
pubmed: 27385944
Crit Rev Biomed Eng. 2009;37(1-2):1-57
pubmed: 20201770
Materials (Basel). 2020 Oct 09;13(20):
pubmed: 33050281
Int J Mol Sci. 2018 Sep 11;19(9):
pubmed: 30208585
J Cell Physiol. 2012 May;227(5):2163-74
pubmed: 21792932
Front Endocrinol (Lausanne). 2020 May 05;11:285
pubmed: 32431670
Osteoarthritis Cartilage. 2002 Jan;10(1):62-70
pubmed: 11795984
Stem Cells Int. 2018 Feb 5;2018:9079538
pubmed: 29535784
Stem Cells Int. 2017;2017:6975251
pubmed: 29445404
Clin Orthop Relat Res. 1994 Jun;(303):18-32
pubmed: 8194231
Tissue Eng Part A. 2014 Mar;20(5-6):1113-26
pubmed: 24152291
Stem Cells Int. 2018 Oct 30;2018:6927401
pubmed: 30510586
Clin Orthop Relat Res. 2013 Jan;471(1):231-7
pubmed: 22961315
Int J Med Sci. 2018 Jan 1;15(1):16-22
pubmed: 29333083
Nutrients. 2019 Jun 03;11(6):
pubmed: 31163658
Stem Cells Int. 2018 Feb 28;2018:6958713
pubmed: 29681950
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S113-6
pubmed: 20864017
Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2924-2934
pubmed: 31002143
J Biomed Mater Res. 1997 Summer;38(2):95-104
pubmed: 9178736
Stem Cells Int. 2017;2017:7617048
pubmed: 28769982
Front Physiol. 2014 Sep 26;5:354
pubmed: 25309452
J Clin Med. 2020 Aug 30;9(9):
pubmed: 32872610
Biomaterials. 2009 Sep;30(26):4277-86
pubmed: 19539365
Eurasian J Med. 2016 Jun;48(2):95-101
pubmed: 27551171
Int J Immunopathol Pharmacol. 2016 Dec;29(4):778-783
pubmed: 27106276
Cell Tissue Bank. 2000;1(4):255-60
pubmed: 15256934
Am J Sports Med. 2002 Jan-Feb;30(1):2-12
pubmed: 11798989
Int J Immunopathol Pharmacol. 2016 Mar;29(1):3-8
pubmed: 26612837
Int J Med Sci. 2018 Jun 13;15(9):944-952
pubmed: 30008608
Adv Healthc Mater. 2020 Nov;9(22):e2001657
pubmed: 33073548
BMC Musculoskelet Disord. 2014 Sep 22;15:309
pubmed: 25245039
Stem Cells Int. 2016;2016:9150819
pubmed: 27956902
Bioengineering (Basel). 2019 Mar 13;6(1):
pubmed: 30871236
Am J Physiol Endocrinol Metab. 2013 Mar 1;304(5):E546-54
pubmed: 23299503
Int J Mol Sci. 2018 Aug 11;19(8):
pubmed: 30103493
Materials (Basel). 2019 Jul 18;12(14):
pubmed: 31323844
Front Cell Dev Biol. 2020 Nov 04;8:580868
pubmed: 33251212
Tissue Eng Part C Methods. 2010 Apr;16(2):291-300
pubmed: 20187869
J Biomed Mater Res A. 2013 Dec;101(12):3542-50
pubmed: 23629940
Materials (Basel). 2015 Aug 31;8(9):5744-5794
pubmed: 28793533
Endocr Metab Immune Disord Drug Targets. 2018;18(5):466-469
pubmed: 29692270